Parexel Becomes SCRS Site Engagement Partner with Contribution to SCRS Diversity Program
Contact:
Jessica Knott
Sr. Communications Manager
Society for Clinical Research Sites
410.696.5080 x120
jessica.knott@myscrs.org
FOR IMMEDIATE RELEASE
Parexel Becomes SCRS Site Engagement Partner with Contribution to SCRS Diversity Program
Hanover, MD, October 31, 2019 – The Society for Clinical Research Sites (SCRS) announced today that Global Impact Partner (GIP), Parexel, has made a commitment to become a funding sponsor of the SCRS Diversity Program, Site Awareness and Best Practices for Inclusion of Diverse Populations in Research. The program is aimed at developing a better understanding of the knowledge, expertise and best practices required for clinical research sites to meet the needs of an increasingly diverse population, and to provide knowledge and solutions to aide sites in more successfully including diverse populations in clinical research.
Parexel’s contribution to the SCRS Diversity Program has aligned the organization as a Site Engagement Partner, further demonstrating their commitment to clinical research sites and their desire to develop a deeper understanding of the needs of sites and contribute to the development and implementation of solutions in the marketplace.
“Parexel understands the importance of diversity in clinical trials and we believe that effective engagement with sites is key to driving progress forward in this regard,” said Gadi Saarony, executive vice president and chief clinical research services officer, Parexel. “SCRS shares our commitment and we look forward to collaborating on key initiatives that will ultimately improve drug development experience for patients.”
Diana Foster, PhD, VP of strategy and special projects for SCRS commented, “Parexel’s decision to support the SCRS Diversity Program marks the first CRO to step forward and join the group as a sponsor of this important work. The program has been supported for three years by industry and is providing cutting edge-initiatives to help guide sites in becoming educated and proactive in enrolling diverse patients in clinical trials. We look forward to the perspective of the Parexel leadership team.”
###
About Parexel
Parexel is focused on supporting the development of innovative new therapies to improve patient health. We do this through a suite of services that help life science and biopharmaceutical customers across the globe transform scientific discoveries into new treatments for patients. From clinical trials to regulatory and consulting services to commercial and market access, our therapeutic, technical and functional ability is underpinned by a deep conviction in what we do. For more information, visit our website and follow us on LinkedIn, Twitter and Instagram.
Parexel is a registered trademark of Parexel International Corporation. All other trademarks are the property of their respective owners.
About SCRS
Founded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit MySCRS.org.
